文章来源于微信公众号：医道社皮肤新前沿，想浏览更多皮肤专业文章请搜索前往！

这项研究首次系统报道了dupilumab在免疫缺陷-移植-罕见病三重难题中的卓越表现，为特殊人群的精准治疗打开了新思路。 研究采用标准化的疗效评估体系，包括湿疹面积和严重程度指数（Eczema Area and Severity Index, EASI）和儿童皮肤病生活质量指数（Children's Dermatology Life Quality Index, CDLQI）。

本研究报道了首例因使用IL-4Rα抑制剂Dupilumab治疗掌跖湿疹-大疱性类天疱疮重叠综合征而继发药物性结肠炎的病例。通过影像学检查（CT结肠成像）、内镜（乙状结肠镜）及组织病理学分析，证实了Dupilumab与急性结肠炎的因果关系，为生物制剂安全性监测提供了重要临床证据，最终通过换用TNF-α抑制 ...

Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new ...

再生元(REGN.US)和赛诺菲(SNY.US)联合开发的重磅疗法Dupixent(dupilumab)获美国FDA批准，用于治疗大疱性类天疱疮(BP)成人患者。根据新闻稿，Dupixent是获美国FDA批准的首款BP疗法。 据悉，BP是一种慢性且易复发的皮肤病，伴有潜在的2型炎症，通常发生于老年人群。其特点为剧烈瘙痒、水疱、皮肤发红及疼痛性病变。水疱和皮疹可能遍布全身，导致皮肤出血和结痂，使患者 ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease remission and significantly improving symptoms like itch and disease ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Patients with atopic dermatitis (AD) treated with dupilumab may face a slightly elevated risk of developing psoriasis, with new study data showing a cumulative 3-year incidence of 2.86% compared ...